Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews...
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • Allergy (Apr 2019)
    • Biology of familial cancer predisposition syndromes (Feb 2019)
    • Mitochondrial dysfunction in disease (Aug 2018)
    • Lipid mediators of disease (Jul 2018)
    • Cellular senescence in human disease (Apr 2018)
    • View all review series...
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Scientific Show Stoppers
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Current issue
  • Past issues
  • By specialty
  • Subscribe
  • Alerts
  • Advertise
  • Contact
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • Brief Reports
  • Technical Advances
  • Commentaries
  • Editorials
  • Hindsight
  • Review series
  • Reviews
  • The Attending Physician
  • First Author Perspectives
  • Scientific Show Stoppers
  • Top read articles
  • Concise Communication
The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes
Bon Ham Yip, … , Andrea Pellagatti, Jacqueline Boultwood
Bon Ham Yip, … , Andrea Pellagatti, Jacqueline Boultwood
Published June 1, 2017; First published April 24, 2017
Citation Information: J Clin Invest. 2017;127(6):2206-2221. https://doi.org/10.1172/JCI91363.
View: Text | PDF | Corrigendum
Categories: Research Article Hematology

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes

  • Text
  • PDF
Abstract

Mutations of the splicing factor–encoding gene U2AF1 are frequent in the myelodysplastic syndromes (MDS), a myeloid malignancy, and other cancers. Patients with MDS suffer from peripheral blood cytopenias, including anemia, and an increasing percentage of bone marrow myeloblasts. We studied the impact of the common U2AF1S34F mutation on cellular function and mRNA splicing in the main cell lineages affected in MDS. We demonstrated that U2AF1S34F expression in human hematopoietic progenitors impairs erythroid differentiation and skews granulomonocytic differentiation toward granulocytes. RNA sequencing of erythroid and granulomonocytic colonies revealed that U2AF1S34F induced a higher number of cassette exon splicing events in granulomonocytic cells than in erythroid cells. U2AF1S34F altered mRNA splicing of many transcripts that were expressed in both cell types in a lineage-specific manner. In hematopoietic progenitors, the introduction of isoform changes identified in the U2AF1S34F target genes H2AFY, encoding an H2A histone variant, and STRAP, encoding serine/threonine kinase receptor–associated protein, recapitulated phenotypes associated with U2AF1S34F expression in erythroid and granulomonocytic cells, suggesting a causal link. Furthermore, we showed that isoform modulation of H2AFY and STRAP rescues the erythroid differentiation defect in U2AF1S34F MDS cells, suggesting that splicing modulators could be used therapeutically. These data have critical implications for understanding MDS phenotypic heterogeneity and support the development of therapies targeting splicing abnormalities.

Authors

Bon Ham Yip, Violetta Steeples, Emmanouela Repapi, Richard N. Armstrong, Miriam Llorian, Swagata Roy, Jacqueline Shaw, Hamid Dolatshad, Stephen Taylor, Amit Verma, Matthias Bartenstein, Paresh Vyas, Nicholas C.P. Cross, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Seishi Ogawa, Christopher W.J. Smith, Andrea Pellagatti, Jacqueline Boultwood

×

Figure 1

Expression of U2AF1S34F impairs erythroid differentiation.

Options: View larger image (or click on image) Download as PowerPoint
Expression of U2AF1S34F impairs erythroid differentiation.
(A) Western b...
(A) Western blots showing expression levels of U2AF1S34F and U2AF1WT protein in transduced erythroid cells harvested on day 11. An anti-U2AF1 antibody was used to measure total U2AF1 protein, while an anti-FLAG antibody was used to measure the exogenous U2AF1S34F or U2AF1WT protein produced by the vector. (B–D) Erythroid differentiation was measured by flow cytometry using expression of CD71 and CD235a cell-surface markers. (B) Nonerythroid (CD71–CD235a–) and (C) intermediate erythroid (CD71+CD235a+) cell populations on day 11 of culture and (D) late erythroid (CD71–CD235a+) cell population on day 14 of culture. (E) Representative flow cytometric plots showing impaired erythroid differentiation on day 14 (n = 8). (F) Image of erythroid cell pellets on day 14 of culture for visual determination of hemoglobinization (n = 8). (G) Number of BFU-E colonies obtained from hematopoietic CD34+ progenitors transduced with EV, U2AF1WT, or U2AF1S34F after 14 days in methylcellulose (colony-forming cell assays). (H) Representative images of BFU-E colonies produced from hematopoietic CD34+ progenitors transduced with EV, U2AF1WT, or U2AF1S34F, respectively (n = 7). Scale bars: 100 μm. (I) Cell counts for U2AF1S34F erythroid cells from day 8 to day 14 of culture compared with counts for EV and U2AF1WT controls. (J) Apoptosis as measured by annexin V staining and flow cytometry in erythroblasts harvested on day 11 of culture. Results shown in panels B–D were obtained from 8 independent experiments, those shown in panels G and I were obtained from 7 independent experiments, and results shown in panel J were obtained from 6 independent experiments. Data represent the mean ± SEM. P values in panels B–D, G, and J were calculated by repeated-measures 1-way ANOVA with Tukey’s post-hoc test. P values in panel I were calculated by 2-way ANOVA with Bonferroni’s post test. *P < 0.05, **P < 0.01, and ***P < 0.001.
Follow JCI:
Copyright © 2019 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts